1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with trifluoperazine in 9 studies
| Studies (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Trials (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Recent Studies (post-2010) (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Studies (trifluoperazine) | Trials (trifluoperazine) | Recent Studies (post-2010) (trifluoperazine) |
|---|---|---|---|---|---|
| 9,156 | 187 | 552 | 3,696 | 157 | 198 |
| Protein | Taxonomy | 1-hexadecyl-2-acetyl-glycero-3-phosphocholine (IC50) | trifluoperazine (IC50) |
|---|---|---|---|
| Genome polyprotein | 0.7 | ||
| Ubiquitin carboxyl-terminal hydrolase 1 | Homo sapiens (human) | 8 | |
| Bile salt export pump | Homo sapiens (human) | 10 | |
| Lysozyme C-1 | Rattus norvegicus (Norway rat) | 9 | |
| Beta-glucuronidase | Rattus norvegicus (Norway rat) | 7.8 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 6.75 | |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 6.226 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.35 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 0.35 | |
| Pleiotropic ABC efflux transporter of multiple drugs | Saccharomyces cerevisiae S288C | 1.4 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.35 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.016 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 6.226 | |
| Nuclear receptor subfamily 3 group C member 3 | Bos taurus (cattle) | 6.226 | |
| WD repeat-containing protein 48 | Homo sapiens (human) | 8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alonso, F; García Gil, M; Gómez-Cambronero, J; Nieto, ML; Sánchez Crespo, M | 1 |
| Filep, J; Frölich, JC; Küster, LJ | 1 |
| Billah, MM; Bryant, RW; Siegel, MI | 1 |
| Lapetina, EG; Siegel, FL | 1 |
| Billah, MM; Siegel, MI | 1 |
| Lapetina, EG; Siess, W; Weber, PC | 1 |
| Levy, JV | 1 |
| Bowman, BJ; Iden, SS; Smith, RJ | 1 |
| Lapetina, EG | 1 |
9 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and trifluoperazine
| Article | Year |
|---|---|
Synthesis of platelet-activating factor from human polymorphonuclear leukocytes: regulation and pharmacological approaches.
Topics: Acetyltransferases; Calcium; Cyclic AMP; Humans; Methylation; Neutrophils; Phosphatidylcholines; Phosphodiesterase Inhibitors; Phospholipids; Platelet Activating Factor; Trifluoperazine | 1985 |
Mechanism of PAF-induced platelet aggregation in man.
Topics: Adult; Aspirin; Blood Platelets; Calcium Channel Blockers; Diterpenes; Female; Ginkgolides; Humans; Kinetics; Lactones; Male; Masoprocol; Plant Extracts; Platelet Activating Factor; Platelet Aggregation; Thromboxane B2; Trifluoperazine | 1986 |
Lipoxygenase products of arachidonic acid modulate biosynthesis of platelet-activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) by human neutrophils via phospholipase A2.
Topics: Acetates; Acetic Acid; Arachidonate Lipoxygenases; Arachidonic Acid; Arachidonic Acids; Calcimycin; Catechols; Humans; Hydroxyeicosatetraenoic Acids; Lipoxygenase; Masoprocol; Membrane Lipids; Neutrophils; Phospholipases; Phospholipases A; Phospholipases A2; Platelet Activating Factor; Trifluoperazine | 1985 |
Shape change induced in human platelets by platelet-activating factor. Correlation with the formation of phosphatidic acid and phosphorylation of a 40,000-dalton protein.
Topics: Blood Platelets; Blood Proteins; Epoprostenol; Humans; Indomethacin; Microscopy, Electron, Scanning; Molecular Weight; Phosphatidic Acids; Phosphorylation; Platelet Activating Factor; Trifluoperazine | 1983 |
Calmodulin antagonists inhibit formation of platelet-activating factor in stimulated human neutrophils.
Topics: Calcimycin; Calcium; Calmodulin; Humans; Kinetics; Neutrophils; Platelet Activating Factor; Sulfonamides; Trifluoperazine | 1984 |
Activation of phospholipase C is dissociated from arachidonate metabolism during platelet shape change induced by thrombin or platelet-activating factor. Epinephrine does not induce phospholipase C activation or platelet shape change.
Topics: Arachidonic Acid; Arachidonic Acids; Aspirin; Blood Platelets; Enzyme Activation; Epinephrine; Humans; Indomethacin; Kinetics; Phospholipases; Platelet Activating Factor; Platelet Aggregation; Thrombin; Trifluoperazine; Type C Phospholipases | 1984 |
Calmodulin antagonists inhibit aggregation of human, guniea pig and rabbit platelets induced with platelet activating factor.
Topics: Animals; Calcium-Binding Proteins; Calmodulin; Dose-Response Relationship, Drug; Female; Guinea Pigs; Humans; Male; Platelet Activating Factor; Platelet Aggregation; Rabbits; Sulfonamides; Trifluoperazine | 1983 |
Characteristics of 1-O-hexadecyl- and 1-O-octadecyl-2-O-acetyl-sn-glyceryl-3-phosphorylcholine-stimulated granule enzyme release from human neutrophils.
Topics: Calcium; Cytochalasin B; Cytoplasmic Granules; Deoxyglucose; Desensitization, Immunologic; Dose-Response Relationship, Immunologic; Exocytosis; Humans; Kinetics; Muramidase; Neutrophils; Platelet Activating Factor; Time Factors; Trifluoperazine | 1983 |
Platelet-activating factor stimulates the phosphatidylinositol cycle. Appearance of phosphatidic acid is associated with the release of serotonin in horse platelets.
Topics: Animals; Arachidonic Acids; Blood Platelets; Epoprostenol; Horses; Kinetics; Lysophosphatidylcholines; Phosphatidic Acids; Phosphatidylinositols; Platelet Activating Factor; Serotonin; Trifluoperazine | 1982 |